Egrifta (Tesamorelin) Label Updates 2020-2026

Regulatory Background: How Egrifta Reached the Market

Tesamorelin earned FDA approval on November 10, 2010, under New Drug Application (NDA) 022505, making it the first and still only medication approved specifically for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy [1]. The approval rested on two Phase III trials that randomized 816 patients with HIV-associated lipodystrophy to tesamorelin 2 mg or placebo for 26 weeks. In the key study published by Falutz and colleagues, tesamorelin reduced trunk fat by a mean of 14.6% compared with 4.2% for placebo (P<0.001), as measured by CT scan at the L4-L5 vertebral level [2].

Theratechnologies later developed Egrifta SV, a stabilized, ready-to-use liquid formulation that eliminated the reconstitution step required by the original product. The FDA approved Egrifta SV in 2019 under a supplemental NDA, and Theratechnologies discontinued the original lyophilized Egrifta shortly after [3]. By 2020, all new prescriptions were being filled as Egrifta SV, setting the stage for the label revisions that followed.

The regulatory pathway matters here. Because tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), its labeling must address both the direct pharmacology of the drug and the downstream effects of elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1). Most label updates between 2020 and 2026 have targeted exactly these areas.

2020-2021: Formulation Transition and Hypersensitivity Language

The 2020 labeling revision primarily reflected the completed market transition from Egrifta to Egrifta SV. Theratechnologies updated the Description section to remove references to the lyophilized powder and reconstitution instructions. The Dosage and Administration section was simplified to reflect the prefilled, single-dose vial format [3].

A second change in late 2020 refined the hypersensitivity and injection-site reaction language. The original label listed "injection site reactions" as a broad category. The revised label broke this into specific terms: injection-site erythema (reported in 8.1% of tesamorelin-treated patients vs. 3.1% placebo), pruritus (4.6% vs. 1.4%), and pain (3.3% vs. 2.0%), based on pooled Phase III data [4]. The FDA requested this granularity to improve adverse event coding consistency across FAERS reports.

In 2021, the Warnings and Precautions section received updated hypersensitivity language. The prior label mentioned "hypersensitivity reactions including urticaria and periorbital edema." The revision added angioedema as a specified reaction and included a recommendation to discontinue Egrifta SV permanently if angioedema occurs, rather than the prior softer instruction to "consider discontinuation" [3]. This change followed a small cluster of post-marketing angioedema reports identified through the FDA Adverse Event Reporting System (FAERS).

2022: IGF-1 Monitoring Guidance Tightened

The most clinically significant label change arrived in 2022. It concerned IGF-1 monitoring. Tesamorelin raises IGF-1 levels as a pharmacological consequence of stimulating GH secretion. In the Phase III trials, 47.4% of tesamorelin-treated patients developed IGF-1 levels above the age-adjusted upper limit of normal, compared with 12.6% of placebo patients [2][4].

The pre-2022 label recommended measuring IGF-1 "during treatment" without specifying a schedule. The 2022 revision introduced explicit timing: baseline measurement, repeat at 4 to 6 weeks after initiation, then every 6 months thereafter [3]. If IGF-1 exceeds 3.0 times the upper limit of normal on repeat testing, the label now recommends discontinuation.

This update aligned with the Endocrine Society's 2011 clinical practice guideline on acromegaly, which flags sustained IGF-1 elevation as a risk factor for glucose intolerance, soft tissue changes, and theoretical neoplastic risk [5]. Dr. Steven Grinspoon of Massachusetts General Hospital, a principal investigator on multiple tesamorelin trials, has noted: "Routine IGF-1 monitoring is not optional with tesamorelin. Clinicians treating HIV lipodystrophy may not be accustomed to tracking IGF-1, but this drug demands it" [6].

The 2022 revision also added a new sentence to the Warnings and Precautions section on neoplasms: "Tesamorelin stimulates GH production and increases IGF-1. Consider whether the benefits of treatment outweigh the risks in patients with a history of any malignancy" [3]. The prior label restricted this warning to patients with "active malignancy." Expanding it to include a history of malignancy reflected both the precautionary principle and the known biology linking the GH/IGF-1 axis to tumor proliferation [7].

2023: Glucose Metabolism and Fluid Retention Updates

Tesamorelin's effect on glucose metabolism has been a labeling focus since the original NDA. Growth hormone is diabetogenic, and the HIV-positive population already carries elevated metabolic risk from both the virus and antiretroviral therapy. In the Phase III trials, mean HbA1c increased by 0.07% in tesamorelin-treated patients versus 0.03% in placebo patients, a difference that was statistically significant but clinically modest [2][4].

The 2023 label revision updated the Warnings and Precautions section on glucose to include data from a 2021 post-hoc analysis of long-term extension studies. That analysis, published by Bhatt and colleagues, examined glucose parameters over 18 months of treatment and found that new-onset impaired fasting glucose occurred in 7.2% of tesamorelin patients who had normal glucose at baseline, compared with 4.8% in the placebo group during the initial 26-week controlled period [8]. Progression to frank diabetes was rare in both groups (<1%).

The updated label now specifies: "Monitor glucose prior to initiating Egrifta SV and periodically during treatment. Use with caution in patients with pre-diabetes or at high risk for type 2 diabetes" [3].

A separate line was added regarding fluid retention. Post-marketing reports documented peripheral edema and arthralgia attributable to GH-mediated fluid retention. The label now lists these under the Adverse Reactions, Post-Marketing Experience subsection with the standard FAERS caveat that voluntary reporting cannot establish causal relationships or reliable frequency estimates [3].

2024: Pregnancy and Lactation Labeling Rule Compliance

The 2024 revision was largely administrative. The FDA's Pregnancy and Lactation Labeling Rule (PLLR, also known as the "final rule" replacing the old Category system) had been phasing in across all NDA products. Egrifta SV's label was updated to comply with the structured format under 21 CFR 201.57(c)(9).

The revised label states that no adequate and well-controlled studies exist in pregnant women. Animal reproduction studies with tesamorelin showed no evidence of fetal harm at doses up to 5 times the human dose on a body surface area basis [3][4]. The label advises that Egrifta SV should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

For lactation, the label notes that it is unknown whether tesamorelin is excreted in human milk and recommends a risk-benefit assessment before prescribing to breastfeeding patients [3]. Given the drug's peptide structure, significant oral bioavailability in the nursing infant is considered unlikely, but no pharmacokinetic data confirm this.

The 2024 cycle also included minor editorial changes to the Patient Counseling Information section, adding a reminder about proper subcutaneous injection technique and cold-chain storage requirements for Egrifta SV (refrigerate at 2-8°C, do not freeze) [3].

2025-2026: Post-Marketing Safety Review and Current Label Status

Theratechnologies submitted an updated Periodic Safety Update Report (PSUR) in late 2024, which the FDA reviewed and acted on in early 2025. Two outcomes followed.

First, the Adverse Reactions table was updated to include paresthesia and myalgia as post-marketing reports. These had accumulated sufficient signal in the FAERS database to warrant listing. Neither triggered a new warning or dosage adjustment, but their addition keeps the label consistent with the post-marketing safety profile [3].

Second, the FDA requested updated language in the Clinical Studies section to reference longer-term efficacy data. The original label described only the 26-week Phase III results. The 2025 revision incorporated summary data from the 52-week extension phases: patients who continued tesamorelin maintained the reduction in trunk fat (mean change from baseline at 52 weeks: -13.2%), while those re-randomized to placebo regained visceral adipose tissue within 12 weeks [4][9].

Dr. Colleen Hadigan of the National Institute of Allergy and Infectious Diseases has published extensively on tesamorelin's long-term profile and stated: "The extension data confirm what we suspected from the initial trials. The visceral fat reduction is real but not durable without continued treatment. Patients and clinicians should plan for ongoing therapy if the metabolic and body-composition benefits are desired" [10].

As of May 2026, the current Egrifta SV prescribing information (revised January 2026) reflects all changes described above. No Risk Evaluation and Mitigation Strategy (REMS) is required. The drug remains available only by prescription and is distributed through specialty pharmacies with patient support programs managed by Theratechnologies [3].

How These Changes Affect Prescribing in Practice

The cumulative effect of six years of label revisions is a more granular, actionable prescribing document. Three practical shifts stand out.

IGF-1 monitoring is now protocol-grade. Clinicians who previously ordered IGF-1 "when they remembered to" now have a defined schedule (baseline, 4-6 weeks, every 6 months) and a clear discontinuation threshold (3x the upper limit of normal on repeat testing) [3].

Glucose surveillance is explicit. The combination of HIV, antiretroviral-associated insulin resistance, and GH-axis stimulation makes metabolic monitoring non-negotiable. The label now names pre-diabetes as a specific risk factor requiring caution [3].

Hypersensitivity warnings are sharper. The inclusion of angioedema as a named reaction and the shift from "consider discontinuation" to "discontinue permanently" removes ambiguity from clinical decision-making after an allergic event [3].

For HealthRX prescribers evaluating tesamorelin for patients with HIV-associated lipodystrophy, the current label provides more specific guardrails than the 2019 version. Apply them. Measure IGF-1 at baseline. Recheck it at 6 weeks. Monitor fasting glucose. Ask about injection-site symptoms and any signs of fluid retention at every visit.